Alpine Immune Sciences Company Overview

Alpine Immune Sciences logo
Alpine Immune Sciences
Alpine Immune Sciences primary media

About Alpine Immune Sciences

Alpine Immune Sciences (NASDAQ:ALPN) is a biotechnology company focused on discovering and developing innovative therapies to modulate the immune system, targeting cancer, autoimmune disorders, and other diseases. With a versatile platform, Alpine is advancing a pipeline of unique candidates designed to engage the immune system through multiple mechanisms. The company's projects leverage its proprietary technologies to create potentially transformative treatments that aim to improve patient outcomes significantly. Alpine Immune Sciences is committed to pushing the boundaries of immunotherapy, striving for breakthroughs that can address unmet medical needs and improve the lives of patients worldwide.

What is Alpine Immune Sciences known for?

Snapshot

2007
Year founded
141
Employees
Seattle, United States
Head office
Loading Map...

Operations

All Locations
Seattle, US

Produtos e/ou serviços de Alpine Immune Sciences

  • ALPN-101, a dual ICOS/CD28 antagonist in development for inflammatory and autoimmune diseases.
  • ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at cancer treatment.
  • ALPN-303, a dual BAFF/APRIL antagonist for B cell mediated diseases.
  • Partnership with AbbVie to develop and commercialize ALPN-101, leveraging AbbVie's global resources for advancement.
  • Collaborations with Adaptimmune for next-generation T-cell therapies, enhancing the effectiveness of cancer immunotherapy.
  • Research and licensing agreement with Kite Pharma to discover and develop protein-based therapeutics for oncology applications.

equipe executiva do Alpine Immune Sciences

  • Dr. Mitchell H. Gold M.D.Executive Chairman & CEO
  • Dr. Stanford Peng M.D., Ph.D.President and Head of Research & Development
  • Mr. Paul RickeySenior VP, CFO, Treasurer & Secretary
  • Ms. M. Christina YiChief Technology Officer
  • Temre JohnsonHead of IR & Corporate Communications
  • Dr. Remy Durand Ph.D.Chief Business Officer
  • Dr. Wolfgang Dummer M.D., Ph.D.Chief Medical Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.